Allergy/Immunology

Feiss G., Morris R., Rom D. et al. (1992). A comparative study of the effects of intranasal triamcinolone acetonide (ITAA) and prednisone on adrenocortical function. The Journal of Allergy and Clinical Immunology, 89(6), 1151-1156.

Howland WC, Dockhorn R, Gillman S, Gross GN, Hille D, Simpson B, Furst JA, Feiss G, Smith JA. A comparision of effects of triamcinolone acetonide aqueous nasal spray, oral prednisone, and placebo on adrenocortical function in male patients with allergic rhinitis. J of Allergy Asthma Immunol. 1996; July: 98(1): 32-38.

Munk ZM, LaForce C, Furst JA, Simpson B, Feiss G, Smith JA. Efficacy and safety of triamcinolone acetonide aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1996; Oct: 77(4): 277-81- Study RG 5029Y-301.

Banov CH, Silvers WS, Green AW, van Bavel JH, Winder JA, Feiss G, Simpson B, Furst JA, Smith JA. Placebo-controlled, double-blind study of the efficacy of triamcinolone acetone aerosol nasal inhaler in pediatric patients with seasonal allergic rhinitis. Clin Ther. 1996 Mar-Apr; 18(2):265-72.- Study RG 5029-121.

Storms WW, Southern DL, Feiss, G, Simpson B, Furst JA, Smith JA. Efficacy of triamcinolone acetonide aerosol nasal inhaler in children with perennial allergic rhinitis. Pediatric Asthma, Allergy & Immunology (submitted 3/96). – Study 5029-120.

Gross, G, Boggs, P, Ginchansky E, Howland W, Munk Z, Weakley S, Alderfer V, Simpson B, Feiss, G, Furst JA, Smith JA. A placebo-controlled double-blind comparison of topical versus systemic triamcinolone aqueous nasal spray in seasonal allergic rhinitis. AM J of Rhinology (submitted 12/95). – Study RG 5029Y-308.

Smith JA, Beaucher WN, Kobayashi RH, Koepke JW, Ransom JH, Rosen JP, Feiss G, Furst JA, Simpson B. Long-term safety and efficacy of triamcinolone acetonide aqueous nasal spray for the treatment of perennial allergic rhinitis. Allergy Asthma Proc 1997 Jan-Feb; 18(1):33-7 Study RG 5029Y-305LT.

Smith JA, Schenkel E, Gross G, Jacobson K, Kobayashi R, Settipane G, Feiss G, Furst J, Simpson B. Efficacy and safety of once-daily triamcinolone acetonide aqueous nasal spray in pediatric patients with spring grass seasonal allergic rhinitis. J of Allergy and Clinical Immunology 1996; 97:197 (No. 1 Pt. 3). Abstracts. – RG 5029Y-312.

LaForce K, Hampel F, Kiechel F, Lumry W, Murray J, Furst JA, Simpson B, Smith JA. Comparison of once-daily triamcinolone acetonide aqueous nasal spray and twice –daily Beconase AQ® for the treatment of seasonal allergic rhinitis due to ragweed. J of Allergy and Clinical Immunology. 1996; 97:433 (No. 1, Pt. 3). Abstract. – Study RG 5029Y-406.

Asthma/COPD

Welch, M.J., Levy, S., Smith, J.A., Feiss, G., Farrar, J.R. (1997). Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma. Chest, 112, 597-606.

Levine, S., Levy, S., Henson, D. (1992). Effect of negative pressure ventilation on ventilatory muscle endurance in patients with severe Chronic Obstructive Pulmonary Disease. Am Rev Res Dis, 146, 722-729.

Braun, S.R., Levy, S., Grossman, J. (1991). Comparison of ipratropium bromide and albuterol in Chronic Obstructive Pulmonary Disease: a three center study. Am J Med., 91, 28-32.

Cardiology

Antman E, McCabe C, Gurfinkel E, Turpie G, Bernink P, Salien D, Bayes De Luna A, Fox K, LaBlanche JM, Radley D, Furst JA, Braunwald E. Treatment Benefit of Enoxaparin in Ustable Angina/Non-Q-Wave Myocardial Infarction is Maintained at One Year Follow-up in TIMI 11B. Abstract accepted for oral presentation at the 72nd annual Scientific Session of the American Heart Association, Atlanta USA, Nov 1999.

Cohen M, Antman E, Gurfinkel E, Turpie A, Furst JA, Bigonzi F Radley R. Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction. Am J Cardiol 2000 Sept 1;86(5):553-6, A9.

Kopecky SL, Aviles RJ, Bell MR, Lobl JK, Tipping D, Frommell G, Ramsey K, Holland AE, Midei M, Jain A, Kellet M, Gibbons RJ. A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study Measuring the Effect of an Adenosine Agonist on Infarct Size Reduction in Patients Undergoing Primary Percutaneous Transluminal Coronary Angioplasty (the ADMIRE [AMP579 Delivery for Myocardial Infarction Reduction] Study), Am Heart J 2003 146:146-52

CNS

Yurko-Mauro, K., McCarthy, D., Rom, D., Nelson, E.B., Ryan, A.S., Blackwell, A., Salem, N. Jr., Stedman, M.; MIDAS Investigators. (2010). Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 6(6), 456-464

Mackin, P., Targum, S.D., Kalali, A., Rom, D., Young, A. (2006). Culture and assessment of manic symptoms. Br J Psychiatry, 189, 379-80.

Dermatology

U. Mrowietz, T. H. Kedem, R. Keynan, M. Eini, D. Tamarkin, D. M. Rom, M. H. Shirvan. A Phase II, Randomized, Double-Blind Clinical Study Evaluating the Safety, Tolerability, and Efficacy of a Topical Minocycline Foam, FMX103, for the Treatment of Facial Papulopustular Rosacea (2018). American Journal of Clinical Dermatology.

Baker, D., Ferris, D., Martens, M., Fife, K., Tyring, S., Edwards, L., Nelson, A., Ault, K., Trofatter, K., Liu, T., Levy, S., & Wu, J. (2011). Imiquimod 3.75% Cream Applied Daily to Treat Anogenital Warts: Combined Results from Women in Two Randomized, Placebo-Controlled Studies. Infectious Diseases in Obstetrics and Gynecology, 2011.

Hanke, C.W., Swanson, N., Bruce, S., Berman, B., Kulp, J., Levy, S. (2011). Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face and balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. J Drugs Dermatol, 10(2), 165-170.

Buchner, L., Vamvakias, G., Rom, D. (2010). Validation of a photonumeric wrinkle assessment scale for assessing nasolabial fold wrinkles. Plastic and Reconstructive Surgery, 126(2), 596-601.

Jorizzo, J., Markowitz, O., Lebwohl, M., Bourcier, M., Kulp, J., Meng, T., Levy, S. (2010). A randomized, double-blind, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol, 9(9), 1101-1108.

Kulp, J., Levy, S., Fein, M.C., Adams, M., Furst, J., Meng, T. (2010). Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp. Arch Dermatol Res., 302, 539-544.

Del Rosso, J.Q., Sofen, H., Leshin, B., Meng, T.C., Kulp, J., Levy, S. (2009). Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses. Clin Aesthetic Dermatol, 2(4), 20-28.
Young, A.L., Levy, S., Nighland, M., Grossman, R., Silvers, S.N., Celebi, J.T. (2009). Are dark-skinned people really protected from ultraviolet radiation? Clin Exp Dermatol.

Eichenfield L.F, Nighland, M., Rossi, A.B., Cook-Bolden, F., Grimes, P., Fried, R., Levy, S. (2008). Phase 4 study to assess tretinoin pump for the treatment of facial acne. J Drugs in Dermatology, 7(12), 112.

Levy, S. et al. (2001). The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: A double- blind clinical trial. American Journal of Clinical Dermatology, 2(1), 33-39.

Kulp J, Levy S, Fein MC, Adams M, Furst J, Meng TC. Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratosis on the face and/or balding scalp. Arch Dermatol Res. 2010 Sep;302(7):539-44. Epub 2010 Mar 4.

Cell Biology

Mallorga, P., Babilon, R., Sugrue, M.F. (1989) Angiotensin II receptors labelled with 125I-[Sar1, Ile8]-AII in albino rabbit ocular tissues Current Eye Research, 8(8):841-9.

Mallorga, P., Babilon, R., Buisson, S., Sugrue, M.F. (1989 May) Muscarinic receptors of the albino rabbit ciliary process. Experimental Eye Research 48(4): 509-22

Vlasuk, G.P., Babilon, R. W., Nutt, R., Ciccarone, T.M. and Windquist, R.J. (1987). The Actions of Atrial Natriuretic Factor on the Vascular Wall. Canadian Journal of Physiology and Pharmacology, 95(8), 1684-1689.

Babilon, R. W., Soprano, K.J. and Henderson, E.E. (1985). Sensitivity of Ataxia-Telangiectasia Lymphoblasts to Low Levels of Neocarzinostatin. Mutation Research, 146, 79-87.

Statistics

Ganju, J. and Rom, D. (2017). Non-inferiority versus superiority drug claims: the (not so) subtle distinction. Trials. 2017 Jun 15;18(1):278. doi: 10.1186/s13063-017-2024-2

Gou, J., Tamhane, C. A., Xi, D., and Rom, D. M.A (2014). class of improved hybrid Hochberg–Hommel type step-up multiple. Biometrika, Volume 101, Issue 4, 1 December 2014, Pages 899–911,

Rom, D. M. (2012). An improved Hochberg procedure for multiple tests of significance British J Math Stat Psychol. 2013 Feb;66(1):189-96

Westfall, P.H., Tobias, R. D., Rom, D. M., Wolfinger, R. D., Hochberg, Y. (1999). Multiple Comparisons and Multiple Tests. SAS Publication

Rom, D. M. and Hwang, E. (1996). Testing for bioequivalence of treatment effects based on the proportion of similar responses. Statistics in Medicine, 15, 1489-1505.

Hochberg Y. and Rom D. M. (1995). Extensions of Simes’ test for logically related hypotheses. Journal of Statistical Planning and Inference, 48, 141-152.

Rom, D. M. and Holland, B. (1995). A new closed multiple testing procedure for hierarchical family of hypotheses. Journal of Statistical Planning and Inference, 46, 265-275.

Chang, C. K., and Rom, D. M. (1994). On the analysis of multiple correlated binary endpoints in medical studies. Proceedings of the Interface between Computing Science and Statistics.

Rom, D. M. (1994). Multiple comparisons, selection and applications in biometry (book review). Biopharmaceutical Report, 2(2), 17.

Rom, D. M. and Connell, L. (1994). A generalized family of multiple test procedures. Communications in Statistics. Theory and Methods, 23(11), 3171-3187.

Rom, D. M., Costello, R. and Connell, L. (1994). On closed test procedures for dose response analysis. Statistics in Medicine, 13, 1583-1596.

Rom, D. M. (1992). Strengthening some common multiple test procedures for discrete data. Statistics in Medicine, 11, 511-514.

Rom, D. M. and Sarkar, S. K. (1992). A generalized model for the analysis of association in ordinal contingency tables. Journal of Statistical Planning and Inference, 33, 205-212.

Rom, D. M. (1990). A sequentially rejective test procedure based on a modified Bonferroni Inequality. Biometrika, 77, 663-665.

Rom, D. M. and Sarkar, S. K. (1990). Approximating probability integrals of multivariate normal using association models. Statistical Computation and Simulation, 35, 109-119.

Rom, D. M. and Sarkar, S. K. (1989). The probability integrals of the multivariate normal: the 2n tree and association models. Proceedings of the Interface between Computing Science and Statistics, 20, 426-431.

Heyse, J. F. and Rom, D. (1988). Adjusting for multiplicity of statistical tests in the analysis of carcinogenicity studies. Biometrical Journal, 30, 883-896.

Anti Infectives

DeAbate CA, Henry D, Bensch G, Jubran A, Chodosh S, Harper L, Tipping D, Talbot GH. Sparfloxacin versus Ofloxacin in the Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis, Chest 1998 114120-130

Donowitz GR, Brandon ML, Salisbury JP, Harman CP, Tipping D, Urick AE, Talbot GH. Sparfloxacin versus Cefaclor in the Treatment of Patients with Community-Acquired Pneumonia: A Randomized, Double-Masked, Comparative, Multicenter Study, Clinical Therapeutics 1997 19(5)936-953

Women's Health

Levine DW, Dailey ME, Rockhill B, Tipping D, Naughton MJ, Shumaker SA. Validation of the Women’s Health Initiative Insomnia Rating Scale in a Multicenter Controlled Clinical Trial, Psychosomatic Medicine 2005 67:98-104

Archer DF, Furst K, Tipping D, Dain MP, VandePol C. A Randomized Comparison of Continuous Combined Transdermal Delivery of Estradiol-Norethindrone Acetate Versus Estradiol Alone for Menopause Treatment, Obstetrics and Gynecology 1999 94(4)498-503

Other

Arterburn, L.M., Oken, HA, Hoffman, JP, Bailey-Hall, E., Chung, G., Rom, D., Hamersley, J., McCarthy D. (2007). Bioequivalence of Docosahexaenoic Acid from Different Algal Oils in Capsules and in a DHA-Fortified Food. Lipids, 42(11), 1011-1024.

Bostom AG, MacLean AA, Maccubbin D, Tipping D, Giezek H, Hanlon WA. Extended-Release Niacin/Laropiprant Lowers Serum Phosphorous Concentrations in Patients with Type 2 Diabetes, J Clin Lipidol 2011 Jul-Aug 5(4):281-7. doi 10.1016/j.jacl.2011.03.455

Ix JH, Ganjoo P, Tipping D, Tershakovec AM, Bostom AG. Sustained Hypophosphatemic Effect of Once-Daily Niacin/Laropiprant in Dyslipidemic CKD Stage 3 Patients, American Journal of Kidney Diseases 2011 June; 57(6):963-5. doi: 10.1053/j.ajkd.2011.03.010

Maccubbin D, Tipping D, Kuznetsova O, Hanlon WA, and Bostom AG. Hypophosphatemic Effect of Niacin in Patients without Renal Failure: A Randomized Trial, Clin J Am Sco Nephrol 2010 April; 5(4): 582–9. doi: 10.2215/CJN.07341009

Goldberg RB., Guyton JR., Mazzone T, Weinstock RS., Polis AB., Tipping D, Tomassini JE., and Tershakovec AM., Relationships Between Metabolic Syndrome and Other Baseline Factors and the Efficacy of Ezetimibe/Simvastatin and Atorvastatin in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia , Diabetes Care 2010 May; 33:1021–4, doi:10.2337/dc09-1762

Kasper CK, Kim HC, Gomperts ED, Smith KJ, Salzman PM, Tipping D, Miller R, Montgomery RM. In Vivo Recovery and Survival of Monoclonal-Antibody-Purified Factor VIII Concentrates, Thrombosis and Haemostasis 1991 66(6)730-733